Hexagon Nutrition Board to Convene EGM for Director Appointments & Remuneration
Hexagon Nutrition's Board noted requisition letters for an EGM to appoint Mr. Arun Purushottam Kelkar as Executive Director and Chairman. Approval for his remuneration and Mr. Vikram Kelkar's remuneration is also sought. The trading window closes October 1, 2026.
The proposed appointment of a new Executive Director and Chairman, along with remuneration approvals, could have a medium-term impact on the company's strategic direction and governance. The EGM requirement signifies a significant corporate action.
The announcement details procedural steps regarding board appointments and remuneration approval via an EGM, as well as a routine trading window closure. It does not contain information that inherently suggests a positive or negative financial or operational outlook for the company.
Hexagon Nutrition Limited announced that its Board of Directors, in a meeting held on September 30, 2026, took note of requisition letters received on September 24, 2026. These letters, from Dr. Nikhil Arun Kelkar and Mr. Vikram Arun Kelkar (holding 38.41% shareholding), requested the convening of an Extra-ordinary General Meeting (EGM) under Section 100 of the Companies Act, 2013.
The proposed agenda for the EGM includes the appointment of Mr. Arun Purushottam Kelkar (DIN: 00171276) as the Executive Director and Chairman, following a notice of candidature under Section 160(1) of the Companies Act, 2013. Additionally, the EGM will seek approval for the remuneration payable to Mr. Arun Purushottam Kelkar for his tenure.
Another requisition letter, dated September 24, 2026, from Dr. Nikhil Arun Kelkar and Ms. Anuradha Kelkar (holding 24.67% shareholding), also requested an EGM to approve the remuneration payable to Mr. Vikram Kelkar, the Managing Director (DIN: 02302364), effective from April 1, 2026.
The Board resolved to convene an EGM to seek member approval for these matters. The board meeting commenced at 11:00 AM and concluded at 11:50 AM.
Furthermore, the company announced that the trading window for dealing in its securities will be closed for all directors, officers, designated persons, and their immediate relatives from October 1, 2026, until 48 hours after the declaration of financial results for the quarter ended September 30, 2026. This information will also be available on the company's website.
What to do with a filing like this
Hexagon Nutrition Limited filed this with the NSE as a statutory disclosure, categorised under board meeting. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Hexagon Nutrition Limited. Read the original for the full detail.